4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1.2B | $210M | 80.2% | 21.1% | -$93M | $319M | $195M |
| 2024 | $1.2B | $7M | 80.6% | 3.2% | $7M | $333M | $319M |
| 2023 | $1.1B | -$126M | 84.1% | -13.9% | -$308M | $240M | $316M |
| 2022 | $901M | -$42M | 83.1% | -8.5% | -$9M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $317M | $89M | 87.4% | 43.2% | -$29M | $486M | $175M |
| Dec '25 | $358M | $102M | 81.6% | 22.6% | -$245M | $319M | $195M |
| Sep '25 | $314M | $42M | 73.2% | 13.7% | -$59M | $322M | $445M |
| Jun '25 | $302M | $18M | 82.8% | 23.8% | $141M | $326M | $510M |
| Mar '25 | $266M | $47M | 83.1% | 24.8% | $70M | $329M | $372M |
| Dec '24 | $299M | $21M | 83.6% | 15.4% | -$33M | $333M | $319M |
| Sep '24 | $307M | $22M | 78.5% | 11.4% | -$5M | — | — |
| Jun '24 | $299M | -$97M | 73.6% | -39.5% | $84M | — | — |
| Mar '24 | $284M | $61M | 86.6% | 26.4% | -$39M | — | — |
How the market has priced INDV against its own fundamentals since 2023-06 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, Indivior Pharmaceuticals, Inc.'s revenue has grown 11.2% per year. These are computed facts, not advice.
As of FY2025, Indivior Pharmaceuticals, Inc. reported $319M of total debt against $195M of cash; operating income covered interest expense 5.8×.
In FY2025, gross margin was 80.2%, operating margin 21.1%, and net margin 16.9%.
As of Jun '26, Indivior Pharmaceuticals, Inc. traded at a price-to-earnings ratio of about 25.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.